These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 24991839)

  • 41. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
    Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
    Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R
    Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
    Yust-Katz S; Liu D; Yuan Y; Liu V; Kang S; Groves M; Puduvalli V; Levin V; Conrad C; Colman H; Hsu S; Yung WK; Gilbert MR
    Cancer; 2013 Aug; 119(15):2747-53. PubMed ID: 23633392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
    Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
    Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
    J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
    Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
    Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
    Ryabaya OO; Inshakov AN; Egorova AV; Emelyanova MA; Nasedkina TV; Zasedatelev AS; Khochenkov DA; Stepanova EV
    Anticancer Drugs; 2017 Mar; 28(3):307-315. PubMed ID: 27941537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
    Patel S; Hurez V; Nawrocki ST; Goros M; Michalek J; Sarantopoulos J; Curiel T; Mahalingam D
    Oncotarget; 2016 Sep; 7(37):59087-59097. PubMed ID: 27463016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
    Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
    Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
    Vogl DT; Stadtmauer EA; Tan KS; Heitjan DF; Davis LE; Pontiggia L; Rangwala R; Piao S; Chang YC; Scott EC; Paul TM; Nichols CW; Porter DL; Kaplan J; Mallon G; Bradner JE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1380-90. PubMed ID: 24991834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
    Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
    Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
    Haas NB; Appleman LJ; Stein M; Redlinger M; Wilks M; Xu X; Onorati A; Kalavacharla A; Kim T; Zhen CJ; Kadri S; Segal JP; Gimotty PA; Davis LE; Amaravadi RK
    Clin Cancer Res; 2019 Apr; 25(7):2080-2087. PubMed ID: 30635337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
    Ridolfi R; Romanini A; Sileni VC; Michiara M; Guida M; Biasco G; Poletti P; Amaducci L; Leoni M; Ravaioli A
    Melanoma Res; 2004 Aug; 14(4):295-9. PubMed ID: 15305161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
    Middleton MR; Friedlander P; Hamid O; Daud A; Plummer R; Falotico N; Chyla B; Jiang F; McKeegan E; Mostafa NM; Zhu M; Qian J; McKee M; Luo Y; Giranda VL; McArthur GA
    Ann Oncol; 2015 Oct; 26(10):2173-9. PubMed ID: 26202595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
    Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E
    Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
    Ma XH; Piao S; Wang D; McAfee QW; Nathanson KL; Lum JJ; Li LZ; Amaravadi RK
    Clin Cancer Res; 2011 May; 17(10):3478-89. PubMed ID: 21325076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.